- Home
- LGVN vs MYNZ Comparison
LGVN vs MYNZ Comparison
Compare LGVN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGVN | MYNZ |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 8.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGVN | MYNZ |
|---|---|---|
| Price | $0.58 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 436.6K | 252.9K |
| Earning Date | 11-04-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,437,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.92 |
| 52 Week High | $2.24 | $8.20 |
Technical Indicators
Market Signals| Indicator | LGVN | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 44.25 |
| Support Level | $0.53 | $1.00 |
| Resistance Level | $0.65 | $1.15 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 35.13 | 46.29 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.